Sava raises $36m in Series B funding led by Ascensia to advance its glucose sensor.
The financing will support manufacturing expansion and commercial launch preparation ahead of clinical trials.
≈ £27.2M at $1 = £0.7554 on 9 Oct 2026
Sava is a London-based medical technology company developing miniature sensors designed to eliminate the need for traditional fingerstick glucose testing for people with diabetes.
London-based Sava has secured $36m in a Series B funding round led by Ascensia, bringing its total capital raised to date to $68m. The company also announced a commercial partnership with Ascensia Diabetes Care to handle distribution in Europe. The new capital will be directed towards scaling manufacturing operations and preparing for market launch.
The round saw participation from a range of existing backers, including Balderton, Pentland, Norrsken, Simplyhealth Ventures, and JamJar Investments. Sava is developing a skin-applied microsensor intended to provide accurate glucose readings and support insulin dosing decisions without requiring conventional fingerstick checks.
Use of funds
- 01Scale operations
- 02Accelerate go-to-market
